Black Diamond Therapeutics Inc (nasdaq:BDTX) Share Price

Company Profile

Business description
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Contact
245 First Street
18th Floor
CambridgeMA02142
USA
T: +1 617 252-0848
https://www.blackdiamondtherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21

Recommended

We think this improves Nvidia’s position within the open-source community.

Brian Colello, CPA | 03 September 2026

Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.

Tom Lauricella | 03 September 2026

Elevated copper prices raise valuation questions.

Tyger Fitzpatrick | 02 September 2026

Index	Last price	Change	% Change
All Ordinaries	9,196.00	54.60	-0.59%
CAC 40	8,277.78	8.62	-0.10%
DAX 40	26,004.84	1.52	0.01%
Dow JONES (US)	53,686.11	624.16	1.18%
FTSE 100	10,827.30	4.22	-0.04%
HKSE	25,650.87	437.56	1.74%
NASDAQ	26,584.06	366.23	1.40%
Nikkei 225	65,020.94	806.46	1.26%
NZX 50 Index	13,974.18	128.00	0.92%
S&P 500	7,747.71	81.11	1.06%
S&P/ASX 200	9,005.90	64.30	-0.71%
SSE Composite Index	3,930.12	11.97	-0.30%